

Japanese Cancer Diagnostics Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies

<https://marketpublishers.com/r/275E36F5E58EN.html>

Date: January 2014

Pages: 590

Price: US\$ 6,080.00 (Single User License)

ID: 275E36F5E58EN

Abstracts

Complete report \$7,600. DataPack (test volumes, sales forecasts, supplier shares) \$4,900.

Summary

This comprehensive report contains 590 pages, 95 tables, and presents analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Japanese cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the Japanese cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Cancer Diagnostic Tests

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals

Commercial/Private Laboratories

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products

Review of over 200 current and emerging cancer diagnostic tests, including:

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Contains 590 pages and 95 tables

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)

- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
 - ADA
 - B-Protein
 - PNP
 - 5'-Nucleotidase
- 27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg
 - Sis
 - Src
- 28. Polypeptide Growth Factors
 - Basic Fibroblast Growth Factor
 - Beta-TGF
 - Cachectin (TNT)
 - Calmodulin
 - ECFR

- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA
- CA 72-4/TAG-72
- CA
- CA-242
- CA-549
- CAM
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18

- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)

- Multiple Tumor Suppressor
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen

C. Instrumentation Review And Market Needs

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview

- ELISA

- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
- d. Fluorescent Immunoassays
- e. Luminescence
 - Chemiluminescence
 - Bioluminescence
- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatography
- e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
 - b. Amplification Methods
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- G. Personal Testing

III. JAPAN

- A. Executive Summary
- B. Business Environment
- C. Market Structure

D. Market Size, Growth and Major Suppliers Sales and Market Shares

X. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XII. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

XIV. COMPETITIVE PROFILES

Abbott
AdnaGen

Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartech
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals
Roche

Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

XV. APPENDIXES:

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications
Appendix II: Assumed Currency Exchange Rates

List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: Japan, Total Tumor Marker Test Volume and Sales

Forecast by Market Segment

Japan, Estimated Cancer Death Rates Per 100,000 Population

Japan, Laboratories Performing Tumor Marker Tests by Market Segment

Japan, Hospital Laboratories Performing Tumor Marker Tests by Bed Size

Japan, Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test Volume

Japan, Total Tumor Marker Testing Volume Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Test Volume Forecast
Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
Japan, Total Tumor Marker Sales Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Sales Forecast by Test
Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Colon-Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
Japan, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, PAP Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, PSA Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Total Tumor Marker Sales by Major Suppliers

Japan, AFP Testing Market Diagnostics Sales by Major Supplier

Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier

Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier

Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier

Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier

Japan, PAP Testing Market Diagnostics Sales by Major Supplier

Japan, PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: Japanese Cancer Diagnostics Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies

Product link: <https://marketpublishers.com/r/275E36F5E58EN.html>

Price: US\$ 6,080.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/275E36F5E58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

